Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo

Natalie A. Hutnick; Devin Jf Myles; Chaoran Billie Bian; Karuppiah Muthumani; David B. Weiner

doi:10.1016/j.coviro.2011.08.003

Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo

Natalie A. Hutnick
, Devin Jf Myles
, Chaoran Billie Bian
, Karuppiah Muthumani
, David B. Weiner

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Abstract

The safety, stability, and ability for repeat homologous vaccination makes the DNA vaccine platform an excellent candidate for an effective HIV-1 vaccine. However, the immunogenicity of early DNA vaccines did not translate from small animal models into larger non-human primates and was markedly lower than viral vectors. In addition to improvements to the DNA vector itself, delivery with electroporation, the inclusion of molecular adjuvants, and heterologous prime-boost strategies have dramatically improved the immunogenicity of DNA vaccines for HIV and currently makes them a leading platform with many areas warranting further research and clinical development.

Original language	English
Pages (from-to)	233-240
Number of pages	8
Journal	Current Opinion in Virology
Volume	1
Issue number	4
DOIs	https://doi.org/10.1016/j.coviro.2011.08.003
State	Published - Oct 2011
Externally published	Yes

Access to Document

10.1016/j.coviro.2011.08.003

Cite this

@article{71e87037d53c4ae1b2860c79c3eacc34,

title = "Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo",

abstract = "The safety, stability, and ability for repeat homologous vaccination makes the DNA vaccine platform an excellent candidate for an effective HIV-1 vaccine. However, the immunogenicity of early DNA vaccines did not translate from small animal models into larger non-human primates and was markedly lower than viral vectors. In addition to improvements to the DNA vector itself, delivery with electroporation, the inclusion of molecular adjuvants, and heterologous prime-boost strategies have dramatically improved the immunogenicity of DNA vaccines for HIV and currently makes them a leading platform with many areas warranting further research and clinical development.",

author = "Hutnick, \{Natalie A.\} and Myles, \{Devin Jf\} and Bian, \{Chaoran Billie\} and Karuppiah Muthumani and Weiner, \{David B.\}",

year = "2011",

month = oct,

doi = "10.1016/j.coviro.2011.08.003",

language = "English",

volume = "1",

pages = "233--240",

journal = "Current Opinion in Virology",

issn = "1879-6257",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo

AU - Hutnick, Natalie A.

AU - Myles, Devin Jf

AU - Bian, Chaoran Billie

AU - Muthumani, Karuppiah

AU - Weiner, David B.

PY - 2011/10

Y1 - 2011/10

N2 - The safety, stability, and ability for repeat homologous vaccination makes the DNA vaccine platform an excellent candidate for an effective HIV-1 vaccine. However, the immunogenicity of early DNA vaccines did not translate from small animal models into larger non-human primates and was markedly lower than viral vectors. In addition to improvements to the DNA vector itself, delivery with electroporation, the inclusion of molecular adjuvants, and heterologous prime-boost strategies have dramatically improved the immunogenicity of DNA vaccines for HIV and currently makes them a leading platform with many areas warranting further research and clinical development.

AB - The safety, stability, and ability for repeat homologous vaccination makes the DNA vaccine platform an excellent candidate for an effective HIV-1 vaccine. However, the immunogenicity of early DNA vaccines did not translate from small animal models into larger non-human primates and was markedly lower than viral vectors. In addition to improvements to the DNA vector itself, delivery with electroporation, the inclusion of molecular adjuvants, and heterologous prime-boost strategies have dramatically improved the immunogenicity of DNA vaccines for HIV and currently makes them a leading platform with many areas warranting further research and clinical development.

UR - https://www.scopus.com/pages/publications/80053366029

U2 - 10.1016/j.coviro.2011.08.003

DO - 10.1016/j.coviro.2011.08.003

M3 - Article

C2 - 22440782

AN - SCOPUS:80053366029

SN - 1879-6257

VL - 1

SP - 233

EP - 240

JO - Current Opinion in Virology

JF - Current Opinion in Virology

IS - 4

ER -

Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo

Abstract

Access to Document

Fingerprint

Cite this